ODE V Deputy Bull To Step In "As Needed" For Novartis-Bound DeLap
This article was originally published in The Tan Sheet
FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD is serving as the office's acting director in areas in which departing Director Robert DeLap, MD/PhD, has potential conflicts of interest.
You may also be interested in...
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Jonca Bull, MD, appointed deputy director, Office of Drug Evaluation V, FDA announces June 22. Bull will move to the new position starting July 30, reporting to ODE V Director Robert DeLap, MD/PhD. Debra Bowen, MD, left the position early this year to join McNeil Consumer Healthcare as VP-clinical research (1"The Tan Sheet" Jan. 3, p. 13). Currently acting director of the Office of Women's Health, Bull previously worked in the Office of the Commissioner as a special assistant and medical advisor to the deputy commissioner for operations. Bull joined FDA in 1994
Perrigo promotes in pricing, planning